BAC
50
-3
MRK
22
3
MS
74
-2
TEL
60
2
JNJ
41
2
ORLY
53
-3
IBM
54
4
TAP
58
-2
AZO
46
-3
MDLZ
34
2
ZBH
60
-2
IP
70
2
WDC
41
-2
AKAM
43
3
DD
56
3
VFC
47
-5
PEP
41
6
EL
20
3
GM
65
-3
HRB
51
2
BAC
50
-3
MRK
22
3
MS
74
-2
TEL
60
2
JNJ
41
2
ORLY
53
-3
IBM
54
4
TAP
58
-2
AZO
46
-3
MDLZ
34
2
ZBH
60
-2
IP
70
2
WDC
41
-2
AKAM
43
3
DD
56
3
VFC
47
-5
PEP
41
6
EL
20
3
GM
65
-3
HRB
51
2
Financhill
Back

Lexicon Pharmaceuticals 10K Form

Sell
20

LXRX
Lexicon Pharmaceuticals

Last Price:
0.79
Seasonality Move:
23.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LXRX News And Ratings

See the #1 stock for the next 7 days that we like better than LXRX

LXRX Financial Statistics

Sales & Book Value

Annual Sales: $1.2M
Cash Flow: $-53.93M
Price / Cash Flow: 0
Annual Sales: $0.49
Price / Book: 1.83

Profitability

EPS (TTM): -0.75000
Net Income (TTM): $-216.39M
Gross Margin: $1.12M
Return on Equity: -115.11%
Return on Assets: -66.89%

Lexicon Pharmaceuticals Earnings Forecast

Key Lexicon Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 25 years for LXRX is 92.94%.
  • The Selling, General & Administrative Expenses for LXRX have been equal to 9,466.94% of Gross Profit Margin.
  • The Research & Development expenses have been 4,890.95% of Revenue.
  • The Interest Expense is -7.40% of Operating Income.
  • The Net Earning history of LXRX is -14,710.88% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 13 years.

Lexicon Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LXRX
CUSIP: 528872
Website: lexpharma.com

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 7.45
Quick Ratio: 7.25

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LXRX Technical Analysis vs Fundamental Analysis

Sell
20
Lexicon Pharmaceuticals (LXRX) is a Sell

Is Lexicon Pharmaceuticals a Buy or a Sell?